ArticleContemporary clinical trials communications2026
Implementation of oncological clinical trials in primary health care in Cuba: a program generalization study.
Article in Contemporary clinical trials communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary health care (PHC) offers a strategic opportunity to conduct research with immunotherapeutic products for cancer treatment. Objectives: To evaluate the implementation of a program for conducting oncological clinical trials in PHC settings. The implementation objectives focused on assessing structure, process, and outcome indicators against predefined standards; the intervention objectives compared process and clinical outcomes (overall survival, quality of life, and patient satisfaction) in PHC settings against a historical control from secondary care. Methods: A longitudinal, prospective, analytical implementation study was conducted in Cuba between January 2016 and August 2023. An open-label, uncontrolled, non-randomized, multicenter, phase IV clinical trial using the CIMAvax-EGF vaccine for patients with advanced lung cancer was used as a case study. The implementation was conducted in three phases: pilot study, replication, and generalization. This paper presents the outcomes of the generalization phase. For evaluation, structure, process, and outcome indicators were assessed against predefined standards and compared with a historical control from secondary health care (SHC). An indicator was considered adequate if it met the standard. The overall dimension (structure, process, or outcome) was considered acceptable if ≥ 70% of its indicators were adequate. Results: The program was implemented in 119 polyclinics nationwide. For structure, 83% (5/6) of indicators were adequate; for process, 83% (5/6) were adequate; for outcome, 100% (4/4) were adequate. All three dimensions met the predefined standards. Process and outcome indicators were comparable or superior to the SHC historical control. Structure and outcome indicators improved after implementation. Conclusions: The results support the feasibility and effectiveness of implementing oncological clinical trials in Cuban PHC centers, demonstrating a positive impact on the target population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.